- Home
- AAMI vs HRMY Comparison
AAMI vs HRMY Comparison
Compare AAMI & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | HRMY |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AAMI | HRMY |
|---|---|---|
| Price | $72.30 | $31.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $58.00 | $44.11 |
| AVG Volume (30 Days) | 351.6K | ★ 696.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $32.73 | $19.75 |
| Revenue Next Year | $14.44 | $12.88 |
| P/E Ratio | ★ $23.86 | $57.31 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $29.26 | $25.52 |
| 52 Week High | $76.13 | $40.87 |
Technical Indicators
Market Signals| Indicator | AAMI | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 57.44 |
| Support Level | $46.04 | $31.61 |
| Resistance Level | $73.10 | $33.11 |
| Average True Range (ATR) | 2.49 | 0.90 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 61.08 | 91.67 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.